Allergan's BOTOX (onabotulinumtoxinA) Receives FDA's Approval for Upper Limb Spasticity in Pediatric Patients
Shots:
- The approval is based on two P-III studies result assessing BOTOX (3-6 units/kg) in 200 pediatric patients with upper limb spasticity aged 2-17yrs. for 12wks. followed by a one-year extension study
- Additionally- sBLA for using BOTOX in treating pediatric patients with lower limb spasticity is under FDA’s review with its expected approval in Q4’19
- BOTOX is a neurotoxin therapy injected in the muscles to treat increased muscle stiffness & eye muscle problems (strabismus) or abnormal spasm of the eyelids (blepharospasm) and has received six-month Priority Review by the FDA
Click here to read full press release/ article | Ref: Allergan | Image: Spicy IP
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com